Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Need for Additional Financing

<< Previous

Bullboard Posts

Next >>

Comment by Harper75on Nov 10, 2023 1:34pm

210 Views

Post# 35728926

RE:RE:Need for Additional Financing

I agree with InTheKnight's opinion. Also, by my calculation, we experienced a 177.5% price increase since Oct 17th lows without much of a pullback. Larger than I wanted as well but we also have had many months in the 40's/50's - doubling up is a tempting profilt to take.

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism